On January 9, Jingtai Technology announced that its subsidiary Ailux Biologics signed a licensing agreement for the macromolecule drug discovery AI platform with the multinational biopharmaceutical company UCB, headquartered in Belgium. According to the agreement, Jingtai Technology commercially licenses UCB to use the Ailux Biologics-developed XtalFold AI platform for the discovery and engineering design of macromolecule drugs. XtalFold is an AI-based Software platform that provides fast and accurate structural information for macromolecule drug development, accelerating innovation across multiple stages of research and development.
晶泰科技与优时比签署大分子药物发现AI平台授权协议
Jingtai Technology and UCB have signed a licensing agreement for an AI platform for macromolecule drug discovery.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha